Powder: -20°C for 3 years | In solvent: -80°C for 1 year
N-acetyl LTE4 is the major inactive metabolite of LTE4 found in bile. This route of metabolism is prominent in the rat, but of minor importance in humans. N-acetyl LTE4 is 100 times less potent than LTC4 as a vasoconstricting agent. In healthy human subjects urinary excretion of N-acetyl LTE4 is about 1.5 nmol/mol creatinine, which is considerably less than that of LTE4 (12 nmol/mol creatinine).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 μg | ¥ 2,880 | 35日内发货 | ||
50 μg | ¥ 5,470 | 35日内发货 | ||
100 μg | ¥ 9,870 | 35日内发货 |
产品描述 | N-acetyl LTE4 is the major inactive metabolite of LTE4 found in bile. This route of metabolism is prominent in the rat, but of minor importance in humans. N-acetyl LTE4 is 100 times less potent than LTC4 as a vasoconstricting agent. In healthy human subjects urinary excretion of N-acetyl LTE4 is about 1.5 nmol/mol creatinine, which is considerably less than that of LTE4 (12 nmol/mol creatinine). |
别名 | N-acetyl Leukotriene E4 |
分子量 | 481.65 |
分子式 | C25H39NO6S |
CAS No. | 80115-95-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMF: >50 mg/mL (per Ramki Iyer)
Ethanol: >50 mg/mL (per Ramki Iyer)
DMSO: >50 mg/mL (per Ramki Iyer)
PBS (pH 7.2): >100 μg/mL (per Ramki Iyer)
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
N-acetyl Leukotriene E4 80115-95-3 N acetyl Leukotriene E4 N-acetyl Leukotriene E-4 Nacetyl Leukotriene E4 Inhibitor inhibitor inhibit